Bob Rappaport News
-
Titan Pharmaceuticals Inc. rose the most in almost four years after U.S. regulatory advisers recommended approval for the company’s experimental implant to treat addiction to heroin and prescription painkillers.
-
Zogenix Inc.’s pure hydrocodone painkiller Zohydro failed to win the backing of U.S. advisers, who said regulators should first take a closer look at measures to curb the abuse of opioids.
-
Pfizer Inc., Johnson & Johnson, and Regeneron Pharmaceuticals Inc. won the backing of a U.S. advisory panel to continue development of a class of experimental painkillers that have been linked to joint failure.
-
A pain patch from NeurogesX Inc., a specialty drugmaker that has never reported an annual profit, may not relieve pain related to nerve damage commonly associated with HIV, U.S. regulators said. The shares plunged 22 percent.
-
NeurogesX Inc. plunged the most in almost three years after U.S. regulators questioned whether the specialty drugmaker proved its patch relieves pain related to nerve damage commonly associated with HIV.
-
Doctors should be aware of the risks of giving the painkiller codeine to children with a certain genetic condition, following reports of three deaths and one illness, the U.S. Food and Drug Administration said.
-
NeurogesX Inc., a specialty drugmaker that has never reported an annual profit, failed to win approval for expanded use of its pain-treating patch and said it will fire 57 percent of workers. The shares fell.
-
U.S. regulators asked an advisory panel whether Pfizer Inc. and Johnson & Johnson, the two biggest U.S. makers of health-care products, should resume human trials on a class of experimental painkillers linked to joint failure.
-
Eli Lilly & Co. , the drugmaker whose top three products face generic competition within three years, won a U.S. panel’s backing to expand use of the antidepressant Cymbalta in chronic knee and lower back pain.
|
|
Most Popular on Bloomberg
|
| |
Rate this Page